Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Metroprolol-succinate

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Metroprolol succinate Manufacturers in India Suppliers Metroprolol succinate Exporters Distributors Metroprolol succinate api active pharmaceuticals ingredients Metroprolol succinate manufacturers Side Effects bulk drugs raw material Metroprolol succinate companies Side Effects Importers Metroprolol succinate Metroprolol succinate Exporters Metroprolol succinate exporters FDA Metroprolol succinate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Metroprolol succinate manufacturing pharmaceutical drugs pharmaceutical intermediates Metroprolol succinate pharmaceutical chemicals pharmaceutical raw materials Metroprolol succinate active pharmaceutical ingredients Metroprolol succinate committee active pharmaceutical ingredients manufacturer Metroprolol succinate Active Pharmaceutical Ingredients manufacturer Metroprolol succinate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Metroprolol succinate, Metroprolol succinate manufacturer India, Metroprolol succinate product, Metroprolol succinate products, Api preparation, Certificate of Analysis API manufacturer product, Metroprolol succinate anti ulcer product, Certificate of Origin COA Metroprolol succinate COS Metroprolol succinate, pharmaceutical generic, pharmaceutical drug, medical, Metroprolol succinate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Metroprolol succinate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Metroprolol succinate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Metroprolol succinate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Metroprolol succinate ingredients, api, HIV Metroprolol succinate, tablets, capsules, syrup & protein Metroprolol succinate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Metroprolol succinate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Metroprolol succinate WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

 long-term treatment of chest pain










 



















 

 

HOME >> Pharmaceuticals API List 2 >> Metroprolol Succinate >> Precautions

Metroprolol succinate, CAS NO 98418-47-4


PRECAUTIONS
Metroprolol succinate CAS NO 98418-47-4

Metoprolol Succinate extended-release tablets should be used with caution in patients with impaired hepatic function. In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.

Worsening cardiac failure may occur during up-titration of Metoprolol Succinate extended-release tablets. If such symptoms occur, diuretics should be increased and the dose of Metoprolol Succinate extended-release tablets should not be advanced until clinical stability is restored. It may be necessary to lower the dose of Metoprolol Succinate extended-release tablets or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of Metoprolol Succinate extended-release tablets.

Patients should be advised to take Metoprolol Succinate extended-release tablets regularly and continuously, as directed, preferably with or immediately following meals. If a dose should be missed, the patient should take only the next scheduled dose (without doubling it). Patients should not interrupt or discontinue Metoprolol Succinate extended-release tablets without consulting the physician.

Patients should be advised
(1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's response to therapy with Metoprolol Succinate extended-release tablets has been determined;
(2) to contact the physician if any difficulty in breathing occurs;
(3) to inform the physician or dentist before any type of surgery that he or she is taking Metoprolol Succinate extended-release tablets.

Heart failure patients should be advised to consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
SIDE EFFECTS
PRECAUTIONS >>
INTERACTION
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Metoprolol Succinate

More Api at Taj Pharmaceuticals Ltd.

Lacidipine

Lamotrigine

Lansoprazole

Levetiracetam

Levo Cetirizine

Levofloxacin

Loratadine

Losartan Potassium

Metoprolol Succinate

Montelukast Sodium

Moxifloxacin HCl

Naproxen

Naratriptan

Norfloxacin

Nizatidine

Olmesartan

Omeprazole

Omeprazole Sodium

Oxaprozin

Paroxetine

Pantoprazole

Primidone

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap
 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.